The Adenoid Cystic Carcinoma (ACC) drugs in development market research report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adenoid Cystic Carcinoma (ACC). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adenoid Cystic Carcinoma (ACC) and features dormant and discontinued products.
GlobalData tracks 44 drugs in development for Adenoid Cystic Carcinoma (ACC) by 41 companies/universities/institutes. The top development phase for Adenoid Cystic Carcinoma (ACC) is phase i with 22 drugs in that stage. The Adenoid Cystic Carcinoma (ACC) pipeline has 41 drugs in development by companies and three by universities/ institutes. Some of the companies in the Adenoid Cystic Carcinoma (ACC) pipeline products market are: Bayer, Eisai and Rgenta Therapeutics.
The key targets in the Adenoid Cystic Carcinoma (ACC) pipeline products market include Programmed Cell Death Protein 1, Transcriptional Activator Myb, and Tubulin.
The key mechanisms of action in the Adenoid Cystic Carcinoma (ACC) pipeline product include Programmed Cell Death Protein 1 Antagonist with five drugs in Phase II. The Adenoid Cystic Carcinoma (ACC) pipeline products include nine routes of administration with the top ROA being Intravenous and eight key molecule types in the Adenoid Cystic Carcinoma (ACC) pipeline products market including Small Molecule, and Monoclonal Antibody.
Adenoid Cystic Carcinoma (ACC) overview
Adenoid cystic carcinoma (ACC) is a rare and aggressive type of cancer that originates from glandular tissues. It can occur in various parts of the body, but it is most found in the salivary glands of the head and neck region. ACC is characterized by a MYB oncogene activation and a tendency to invade nerves and metastasize to distant organs. The treatment options for ACC include surgery, radiotherapy, and chemotherapy, depending on the stage and location of the tumor. ACC has a high five-year survival rate, but it often recurs after many years and has a poor long-term prognosis.
For a complete picture of Adenoid Cystic Carcinoma (ACC)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
